Clinical Trials Sponsored by VIBRAINT RUS LLC

Total 142 results

RFS Pharma, LLC

Withdrawn

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Human Immunodeficiency Virus Infection
RFS Pharma, LLC

Terminated

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

Human Immunodeficiency Virus Infection

Argentina
RFS Pharma, LLC

Completed

Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV

HIV Infections

Argentina
Curium US LLC

Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)

Prostate Cancer | Prostate Adenocarcinoma | Biochemical Recurrence of Malignant Neoplasm of Prostate

United States
Curium US LLC

Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

Prostate Cancer | Prostate Adenocarcinoma

United States
Amivas (US), LLC

Recruiting

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

Pregnancy | Malaria

United States
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Curium US LLC

Completed

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Metastasis From Malignant Tumor of Prostate (Disorder)

United States
Curium US LLC

Approved for marketing

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Neuroendocrine Tumors
XOMA (US) LLC

Terminated

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States, Australia, Canada
XOMA (US) LLC

Completed

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
XOMA (US) LLC

Suspended

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

United States
XOMA (US) LLC

Completed

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
XOMA (US) LLC

Completed

Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

Adenocarcinoma

United States
Curium US LLC

Active, not recruiting

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Metastasis From Malignant Tumor of Prostate

United States, France, Spain, Italy
XOMA (US) LLC

Terminated

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
XOMA (US) LLC

Terminated

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States, Australia, Canada
XOMA (US) LLC

Terminated

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis (EYEGUARD™-US)

Behcet's Disease Uveitis

United States
US CosmeceuTechs, LLC

Completed

Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage

Skin Manifestations
XOMA (US) LLC

Completed

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
XOMA (US) LLC

Completed

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

Type 2 Diabetes

Switzerland
XOMA (US) LLC

Completed

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

Psoriatic Arthritis
XOMA (US) LLC

Completed

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

Rheumatoid Arthritis

United States
XOMA (US) LLC

Completed

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery (XOMA 358)

Hypoglycemia

United States
XOMA (US) LLC

Completed

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United Kingdom, United States
XOMA (US) LLC

Terminated

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data (EYEGUARD™-E)

Uveitis

United States
XOMA (US) LLC

Completed

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Osteoarthritis

United States
XOMA (US) LLC

Completed

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
XOMA (US) LLC

Terminated

Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (HSCT)

Graft Versus Host Disease

United States
XOMA (US) LLC

Completed

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Type 2 Diabetes Mellitus

United States
Fusion Pharma LLC
Data Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation Center

Unknown

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid Leukemia

Russian Federation
Aphaia Pharma US LLC

Recruiting

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT)

PreDiabetes | Glucose Tolerance Impaired

Slovakia
Kira Pharmacenticals (US), LLC.

Not yet recruiting

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Glomerulonephritis
Aphaia Pharma US LLC

Recruiting

A Study of Distal Jejunal-release Dextrose in Obese Participants

Obese

Germany, Puerto Rico
Kira Pharmacenticals (US), LLC.

Not yet recruiting

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Osmotica Pharmaceutical US LLC

Completed

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

Parkinson's Disease

Argentina
Kira Pharmacenticals (US), LLC.

Not yet recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Paroxysmal Nocturnal Hemoglobinuria

China
Nutrabiotix, LLC
Rush University Medical Center

Terminated

Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)

Constipation-predominant IBS (IBS-C)

United States
SciTech Development, LLC
Rush University Medical Center

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditions

United States
Jovie USA, LLC
IQVIA RDS Inc.; ObvioHealth

Completed

Growth and Safety Clinical Trial on a New Infant Formula

Weight Gain

United States
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoPac
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

Locally Advanced Pancreatic Adenocarcinoma

United States
NanOlogy, LLC
US Biotest, Inc.

Terminated

Trial of NanoPac Focal Therapy for Prostate Cancer

Urogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer Adenocarcinoma

United States
USWM, LLC (dba US WorldMeds)

Suspended

Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal (TAPER)

Opioid Withdrawal (Disorder)

United States
NanOlogy, LLC
US Biotest, Inc.

Withdrawn

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal
NanOlogy, LLC
US Biotest, Inc.

Available

Expanded Access to NanoDoce

Urogenital Neoplasms
NanOlogy, LLC
US Biotest, Inc.

Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Cancer | Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Urinary Bladder Neoplasm | Cancer of the Bladder | Malignant Tumor of the Urinary Bladder

United States

3

Subscribe